Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The "Global Angina Pectoris Drugs Market by Type, Drugs, Route of Administration, End-Users - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Forecast 2023-2030" report has been added to ResearchAndMarkets.com's offering.
The global angina pectoris drugs market, valued at USD 1.09 billion in 2022, is poised for substantial expansion.
According to the latest market research report, the market is projected to achieve a Compound Annual Growth Rate (CAGR) of 5.32%, reaching an estimated USD 1.14 billion in 2023 and ultimately surging to USD 1.65 billion by the year 2030.
Market Segmentation & Coverage:
This comprehensive report categorizes the global angina pectoris drugs market into key segments, enabling precise revenue forecasting and trend analysis within each sub-market:
Type: The market is studied across three types of angina pectoris: Prinzmetal Angina, Stable Angina, and Unstable Angina. Notably, Unstable Angina is expected to witness significant market share during the forecast period.
Drugs: Analysis extends to various drug categories, including Anti-Ischemic Agents, Antihypertensive Agents, Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Nitrates, and Statins. Among these, Antihypertensive Agents are projected to hold a significant market share during the forecast period.
Route of Administration: The report explores different routes of administration, including Oral, Parenteral, and Transdermal. The Oral route is expected to dominate the market share throughout the forecast period.
End-Users: The market analysis encompasses end-users such as Homecare, Hospitals, and Specialty Clinics. Specialty Clinics are projected to command a significant market share during the forecast period.
Region: The global angina pectoris drugs market is analyzed across key regions, including the Americas, Asia-Pacific, and Europe, Middle East & Africa (EMEA). Within the Americas, specific attention is given to Argentina, Brazil, Canada, Mexico, and the United States. Further granularity is provided for the United States, including California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. In the Asia-Pacific region, the analysis covers Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The EMEA region is extensively studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, the United Arab Emirates, and the United Kingdom. Notably, the Americas region is projected to witness significant market share during the forecast period.
Market Dynamics:
Drivers: The report identifies several drivers stimulating market growth, including the increasing burden of lifestyle diseases coupled with a rise in heart-related disorders, the augmentation of novel drug delivery systems, and government support in strengthening the prevention and control of cardiovascular diseases.
Restraints: A lack of skilled professionals is recognized as a challenge in the market.
Opportunities: The report highlights opportunities arising from technological advancements toward personalized cardiovascular medicine and the proliferation of drug approvals and clinical research.
Challenges: Concerns related to side effects associated with certain drug classes are acknowledged as challenges in the market.
Key Insights and Deliverables:
The report offers valuable insights and answers key questions for stakeholders:
- Market Penetration: Comprehensive information on the market is provided by key players.
- Market Development: In-depth details about lucrative emerging markets and penetration across mature segments are analyzed.
- Market Diversification: The report offers detailed information on new product launches, untapped geographies, recent developments, and investments.
- Market Trends: A comprehensive understanding of the cumulative impact of COVID-19, the Russia-Ukraine Conflict, and high inflation is provided.
- Competitive Assessment & Intelligence: The report exhaustively assesses market shares, strategies, products, certifications, regulatory approvals, patent landscapes, and manufacturing capabilities of leading players.
- Product Development & Innovation: Intelligent insights are presented on future technologies, R&D activities, and breakthrough product developments.
Key Attributes:
- Number of Pages: 180
- Forecast Period: 2023 - 2030
- Estimated Market Value (USD) in 2023: $1.14 Billion
- Forecasted Market Value (USD) by 2030: $1.65 Billion
- Compound Annual Growth Rate: 5.3%
- Regions Covered: Global
The global angina pectoris drugs market is on the verge of significant expansion, driven by advancements in treatment options and a rising prevalence of cardiovascular diseases. With opportunities on the horizon and dynamic market forces at play, the future of this market holds promise for both existing and new participants.
Companies Mentioned
- Alivira Animal Health Limited
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Bayer AG
- Carl Zeiss Meditec AG
- Eli Lilly and Company
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Merck & Co. Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Sanofi-Aventis Groupe S.A.
- Sumitomo Corporation
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/96imfv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
